TD Asset Management
AMRX icon

TD Asset Management’s Amneal Pharmaceuticals AMRX Stock Holding History

TD Asset Management’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-267,808
Closed -$777K – 1395
2019
Q3 		$777K Sell
267,808
-172,367
-39% -$601K ﹤0.01% 1104
2019
Q2 		$3.16M Sell
440,175
-42,000
-9% -$429K ﹤0.01% 807
2019
Q1 		$6.83M Buy
482,175
+15,300
+3% +$202K 0.01% 617
2018
Q4 		$6.32M Buy
466,875
+232,043
+99% +$4.18M 0.01% 595
2018
Q3 		$5.21M Buy
+234,832
New +$4.94M 0.01% 716

Other funds holding AMRX

FI
Fosun International Hong Kong, China $446M AUM 13.33% 1-Year Est. Return
TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

TD Asset Management's AMRX Position: Q4 2019 in Review

TD Asset Management sold out of Amneal Pharmaceuticals (AMRX) in Q4 2019, closing a stake of 267,808 shares — an estimated $777K sold.

TD Asset Management first reported a position in AMRX in Q3 2018 and held it in 5 quarters. The position peaked at $6.83M in Q1 2019. 129 funds tracked by Wall St. Rank hold AMRX as of Q4 2019.

  • TD Asset Management reported no remaining Amneal Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
  • TD Asset Management sold 267,808 Amneal Pharmaceuticals shares in Q4 2019, an estimated $777K.
  • TD Asset Management first reported a position in Amneal Pharmaceuticals in Q3 2018 and held it in 5 quarters.
  • TD Asset Management's Amneal Pharmaceuticals position peaked at $6.83M in Q1 2019.
  • 129 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q4 2019.

Based on TD Asset Management's 13F filing for Q4 2019, filed 11 Feb 2020.